Compare Orion Office REIT Inc (ONL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Tango Therapeutics Inc. — how do they compare? Orion Office REIT Inc trades at $2.11 (market cap $119.79M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 31.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 34 Days and Tango Therapeutics Inc. for 0 Days on average.
| ONL | TNGX | |
|---|---|---|
Market Cap | $119.79M | $3.74B |
Volume | 347,277 | 3,438,781 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $32.90 |
52-Week Low | $1.93 | $7.50 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $536.73M | $2.76B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.10, down 2.33% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported Q2 2026 EPS of $0.42, beating expectations, but maintains negative net income margins and declining revenue trends from $208M in 2022 to $148M in 2025. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook remains challenging with persistent net losses and high debt levels, though the deep discount to book value (P/B 0.19) offers potential upside if operational improvements materialize. Key risks include ongoing revenue contraction, negative profitability, and significant leverage exposure in the office REIT sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
